Skip to content

Drug-Coated Balloon versus Drug-Coated Balloon with atherectomy for the Treatment of Femoral-Popliteal calcified occlusive disease: a Randomized, Controlled and Prospective study

Drug-Coated Balloon versus Drug-Coated Balloon with atherectomy for the Treatment of Femoral-Popliteal calcified occlusive disease: a Randomized, Controlled and Prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17012486
Enrollment
Unknown
Registered
2017-08-28
Start date
2017-10-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peripheral Arterial Disease

Interventions

experimental group:Drug-Coated Balloon combined with atherectomy
controlled group:Drug-Coated Balloon

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. patient will be more than or equal to 18 years of age and younger than 80 years, male or female; 2. diagnosed with femoral-popliteal calcified occlusive disease; 3. ultrasound or CTA confirm that calcification exists at least one plane; 4. possess operation indication; 5. no operation contraindication; 6. participate in clinical trial, accept interference and be followed voluntarily.

Exclusion criteria

Exclusion criteria: 1. allergy to paclitaxel; 2. symptomatic myocardial infarction occured in the past 3 months, or unstable angina occured more than or equal to 3 times in the past one month, or severe heart failure can not be well controled by medicine; 3. suffer from severe respiratory insufficiency 4. suffer from severe renal insufficiency; 5. suffer from severe hepatic disease; 6. suffer from therioma or other severe disease, and expectation of life is less than 6 months.

Design outcomes

Primary

MeasureTime frame
primary patency rate;rate of target lesion revascularization;

Secondary

MeasureTime frame
intermittent claudication;critical lower-extremity ischemic;amputation rate;all-cause mortality;

Countries

China

Contacts

Public ContactGuo Wei

Chinese PLA General Hospital

pla301dml@vip.sina.com+86 13910758706

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026